Bibliography
- McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001;33(5):641-7
- Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44
- Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-17
- Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26(4):781-803
- Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38(2):161-89
- Anidulafungin (Eraxis®) Prescribing Information. Pfizer® 2007.
- United States Food and Drug Administration. Washington DC. FDA Approved Drug Products. Available from: http://www.fda.gov [Last accessed 3 March 2008]
- European Medicines Agency. London, United Kingdom. Available from: http://www..emea.europa.eu. [Last accessed 11 March 2008]
- Wagner C, Graninger W, Presterl E, Joukhadar C. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006;78(4):161-77
- Eschenauer G, DePestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007;3(1):71-97
- Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993;6(1):1-21
- Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46(9):3001-12
- Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994;38(7):1480-9
- Roling EE, Klepser ME, Wasson A, et al. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002;43(1):13-7
- Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008;46(3):842-9
- Arikan S, Yurdakul P, Hascelik G. Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother 2003;47(8):2640-3
- Watabe E, Nakai T, Matsumoto S, et al. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 2003;47(6):1995-8
- Antachopoulos C, Meletiadis J, Sein T, et al. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008;52(1):321-8
- Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47(10):3149-54
- Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005;43(11):5425-7
- Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998;42(10):2726-30
- Serrano Mdel C, Valverde-Conde A, Chavez MM, et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366)and amphotericin B against aspergillus spp. Diagn Microbiol Infect Dis 2003;45(2):131-5
- Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997;41(4):863-5
- Philip A, Odabasi Z, Rodriguez J, et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005;49(8):3572-4
- Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005;49(8):3264-73
- Laverdiere M, Lalonde RG, Baril JG, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57(4):705-8
- Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005;49(2):767-9
- Ali A, Vasquez G, Vager D, et al. Pharmacodynamics of echinocandins against Candida spp, including strains with reduced susceptibility to micafungin and caspofungin while retaining anidulafungin activity [abstract M-538]. Presented at 47th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), 2007; Chicago, IL
- Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44(6):590-8
- Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50(2):632-8
- Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007;47(4):461-70
- Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39(6):770-5
- Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005;45(12):1373-82
- Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005;45(2):227-33
- Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005;49(12):5058-68
- Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999;43(9):2148-55
- Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004;23(11):805-12
- Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004;190(8):1464-71
- Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45(10):2845-55
- Gumbo T, Drusano GL, Liu W, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006;50(11):3695-700
- Andes D, Marchillo K. In vivo pharmacodynamic characterization of a new echinocandin, anidulafungin, against Candida albicans and Candida glabrata in the neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2008;52(2):539-50
- Kelley K, Chapman S, Cleary JD. Digestion of echinocandins [abstract M-366]. Presented at 46th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 2006; San Francisco, CA
- de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39(6):842-9
- Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113(4):294-9
- Vazquez JA, Schranz JA, Clark K, et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008;48(3):304-9
- Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48(6):2021-4
- Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82
- Brielmaier BD, Casabar E, Kurtzeborn CM, et al. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 2008;28(1):64-73
- Hurren JR, Davis SL, Vazquez JA. What is the risk of disulfiram-like reaction during anidulafungin and metronidazole administration? [abstract K-2158]. Presented at 47th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 2007; Chicago, IL
- Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45(7):883-93
- Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9
- Caspofungin (Cancidas®) Prescribing Information. Merck & Co., Inc. 2005.
- Micafungin (Mycamine®) Prescribing Information. Astellas Pharma US, Inc. 2008.
- Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005;33(5):676-82
- Odds FC, Brown AJ, Gow NA. Trends Microbiol 2003;11(6):272-9